Related references
Note: Only part of the references are listed.Mammalian Target of Rapamycin: Its Role in Early Neural Development and in Adult and Aged Brain Function
Carla Garza-Lombo et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2016)
mTORC2 regulates PGE2-mediated endothelial cell survival and migration
Shirine Dada et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Tyrosine phosphatase SHP-2 is a regulator of p27Kip1 tyrosine phosphorylation
Irini Tossidou et al.
CELL CYCLE (2008)
Spy1 enhances phosphorylation and degradation of the cell cycle inhibitor p27
Christopher W. McAndrew et al.
CELL CYCLE (2007)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Pathological correlates of late drug-eluting stent thrombosis - Strut coverage as a marker of endothelialization
Aloke V. Finn et al.
CIRCULATION (2007)
Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents
Adnan Kastrati et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Stent thrombosis in randomized clinical trials of drug-eluting stents
Laura Mauri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents
Christian Spaulding et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents
Gregg W. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2
Isabel Chu et al.
CELL (2007)
Cdk-inhibitory activity and stability of p27Kip1 are directly regulated by oncogenic tyrosine kinases
Matthias Grimmler et al.
CELL (2007)
Antianglogenic potential of the mammalian target of rapamycin inhibitor temsirolimus
Donatella Del Bufalo et al.
CANCER RESEARCH (2006)
Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB
DD Sarbassov et al.
MOLECULAR CELL (2006)
mTOR•RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes
RC Hresko et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma
TE Witzig et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
A simple method of isolating mouse aortic endothelial cells
M Kobayashi et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2005)
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
DD Sarbassov et al.
SCIENCE (2005)
Rho-kinase and myosin II activities are required for cell type and environment specific migration
M Nakayama et al.
GENES TO CELLS (2005)
p27Kip1 modulates cell migration through the regulation of RhoA activation
A Besson et al.
GENES & DEVELOPMENT (2004)
Analysis of 1-year clinical outcomes in the SIRIUS trial - A randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis
DR Holmes et al.
CIRCULATION (2004)
Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton
DD Sarbassov et al.
CURRENT BIOLOGY (2004)
Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive
E Jacinto et al.
NATURE CELL BIOLOGY (2004)
Cell migration: Integrating signals from front to back
AJ Ridley et al.
SCIENCE (2003)
Coordinate control of proliferation and migration by the p27Kip1/cyclin-dependent kinase/retinoblastoma pathway in vascular smooth muscle cells and fibroblasts
A Díez-Juan et al.
CIRCULATION RESEARCH (2003)
Distinct regulation of mitogen-activated protein kinases and p27Kip1 in smooth muscle cells from different vascular beds -: A potential role in establishing regional phenotypic variance
C Castro et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Deregulated degradation of the cdk inhibitor p27 and malignant transformation
J Bloom et al.
SEMINARS IN CANCER BIOLOGY (2003)
Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action
K Hara et al.
CELL (2002)
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor
M Guba et al.
NATURE MEDICINE (2002)
A mouse knock-in model exposes sequential proteolytic pathways that regulate p27Kip1 in G1 and S phase
NP Malek et al.
NATURE (2001)
Signaling through CD28 and CTLA-4 controls two distinct forms of T cell anergy
AD Wells et al.
JOURNAL OF CLINICAL INVESTIGATION (2001)
Overexpression of p27Kip1 by doxycycline-regulated adenoviral vectors inhibits endothelial cell proliferation and migration and impairs angiogenesis
D Goukassian et al.
FASEB JOURNAL (2001)
Cell cycle protein expression in vascular smooth muscle cells in vitro and in vivo is regulated through phosphatidylinositol 3-kinase and mammalian target of rapamycin
RC Braun-Dullaeus et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2001)
Role for p27Kip1, vascular smooth muscle cell migration
J Sun et al.
CIRCULATION (2001)
Share Paper
